SANGEL CAPITAL
Sangel Capital as one of the earliest globally operating professional biomedical venture capital institutions was established in China in 2010, focusing on life science and technology, and having leading professional advantages and rich project resources in the biomedical investment industry. Sangel Capital has offices in Shenzhen, Beijing, Suzhou, and Chicago. We bring together a group of investment and advisory teams composed of industry experts, scientists, and investors in the field of life technology to manage and operate a series of RMB and USD funds.
SANGEL CAPITAL
Social Links:
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
SPF Euro Pound Sterling Japanese Yen China Telecom Tencent QQ Mail
Similar Organizations
Fortune Venture Capital
Fortune Capital, established in April, 2000, is one of the earliest market-oriented venture capital firms in China.
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2022-03-15 | Yiyao Technology | Sangel Capital investment in Angel Round - Yiyao Technology | 10 M CNY |
2021-12-31 | SparX Group | Sangel Capital investment in Series B - SparX Group | 30 M USD |
2021-03-10 | Aucta Pharmaceuticals China | Sangel Capital investment in Series A - Aucta Pharmaceuticals China | N/A |
2020-12-10 | Denovo Biopharma | Sangel Capital investment in Series D - Denovo Biopharma | 300 M CNY |
2020-10-23 | Sirnaomics | Sangel Capital investment in Series D - Sirnaomics | 105 M USD |
2020-10-19 | 3D Medicines | Sangel Capital investment in Private Equity Round - 3D Medicines | 1.5 B CNY |
2020-06-07 | Virogin Biotech | Sangel Capital investment in Series B - Virogin Biotech | N/A |
2019-10-31 | Denovo Biopharma | Sangel Capital investment in Series B - Denovo Biopharma | 300 M CNY |
2019-04-04 | BrainNow | Sangel Capital investment in Series A - BrainNow | N/A |
2019-02-13 | Magpie Pharmaceuticals | Sangel Capital investment in Series B - Magpie Pharmaceuticals | 100 M CNY |